EPZ004777 hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I001466
  • CAS Number: 1380316-03-9
  • Molecular Formula: C28H41N7O4.HCl
  • Molecular Weight: 576.13
  • Purity: ≥95%
Inquiry Now

EPZ004777 hydrochloride(Cat No.:I001466) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme involved in the regulation of gene expression through histone modifications. It acts by binding to the catalytic domain of LSD1, inhibiting its demethylase activity. EPZ004777 hydrochloride has demonstrated potent antiproliferative activity against cancer cells, particularly in leukemia and neuroblastoma models. It is being investigated as a potential therapeutic agent for the treatment of various cancers and other diseases associated with dysregulated histone methylation.


Catalog Number I001466
CAS Number 1380316-03-9
Synonyms

1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea;hydrochloride

Molecular Formula C28H41N7O4.HCl
Purity ≥95%
Target Histone Methyltransferase
Solubility 10 mM in DMSO
Storage 4°C, protect from light
IC50 0.4 nM
IUPAC Name 1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea;hydrochloride
InChI InChI=1S/C28H41N7O4.ClH/c1-17(2)34(13-6-12-30-27(38)33-19-9-7-18(8-10-19)28(3,4)5)15-21-22(36)23(37)26(39-21)35-14-11-20-24(29)31-16-32-25(20)35;/h7-11,14,16-17,21-23,26,36-37H,6,12-13,15H2,1-5H3,(H2,29,31,32)(H2,30,33,38);1H/t21-,22-,23-,26-;/m1./s1
InChIKey NPEPLDAFAVXSBD-XRJUUMFPSA-N
SMILES CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O.Cl
Reference

<p style=/line-height:25px/>
<br>[1]. Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53-65.

<br>[2]. Chen L, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22.

<br>[3]. Deshpande AJ, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.Blood. 2013 Mar 28;121(13):2533-41.

</p>

Request a Quote